Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase 2, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Chronic Spontaneous Urticaria Despite H1-antihistamine Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Urticaria
- Focus Proof of concept; Therapeutic Use
- Acronyms DUPICSU
- 08 Oct 2021 Status changed from recruiting to completed.
- 11 Oct 2018 New trial record